CureVac raises $105M to advance therapeutic cancer vaccines

09/19/2012 | BioWorld Online

Germany's CureVac secured $104.9 million in private equity financing from dievini Hopp BioTech Holding. The proceeds will help advance the development of CureVac's mRNA-based therapeutic prostate cancer vaccine, CV9103, and nonsmall-cell lung cancer vaccine, CV9201.

View Full Article in:

BioWorld Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC